WHO Issues Concern Over Severe Scarcity of Obesity Injections

Under a tenth of people who could benefit from obesity jabs such as Wegovy can access them, states the World Health Organization as it publishes its first guidance on the therapies.

Given more than one billion people worldwide now classified as obese, it is urging increased and just availability to these injectable treatments.

Per projections, over two billion could be obese by 2030 if no action is taken.

"Our latest guidance acknowledges that excess weight is a long-term condition that can be addressed with thorough and ongoing treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.

Significant expense, limited production capacity, and logistical bottlenecks are significant hurdles to broad availability to the jabs that can assist patients in reducing substantial body mass, says the body.

Skinny Jab Supply Crisis

Despite the present most optimistic case, the supply of such drugs could only cover around 100 million people – fewer than 10% of eligible patients, per the WHO.

The recommendation urges countries and companies to expand availability, via strategies like patent sharing.

A patent on the active ingredient – the core ingredient of Novo Nordisk's Wegovy – is scheduled to end in several nations in 2026.

How Weight-Loss Drugs Function

These medications replicate a body's own hormone to slow digestion, reduce hunger and enhance satiety so users reduce food intake.

Patients commonly start to lose weight after several weeks of beginning the weekly injections.

Research indicates patients may see weight return after a year of discontinuing the treatment, as their typical appetite come back.

To be overweight or obese elevates your risk for developing diseases, such as diabetes, cardiovascular issues, brain attack, and specific cancers.

Obesity impacts people in every country and was responsible for over three and a half million deaths worldwide in 2024, as per the WHO.